MIND MEDICINE (MINDMED) INC

MindMed is a clinical-stage biotechnology company developing psychedelic-inspired medicines. Its research pipeline includes LSD and psilocybin analogs for conditions like anxiety disorders. The development of these novel therapeutics requires extensive preclinical testing, which involves the use of animals to assess pharmacology, toxicology, and abuse potential. Standard regulatory pathways for drug approval mandate such animal studies to evaluate safety and efficacy before human trials can proceed. This places the company's core research and development activities within the scope of commercial animal testing.

While the specific scale of MindMed's animal testing is not detailed in public filings, the nature of its work—advancing multiple drug candidates through the FDA pipeline—implies a material and ongoing reliance on animal models. The company’s research collaborations, such as with NYU Langone, further indicate engagement with institutions conducting this necessary preclinical work.